A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the effectiveness and safety of IBI362 in patients with type 2 diabetes (T2D) with poor glycemia control only through diet and exercise. This study plans to enroll about 300 T2D subjects who still fail to meet the HbA1c standard after at least 2 months of simple diet and exercise control. During the whole study, subjects will be required to maintain diet and exercise control.

The whole trial period includes a 2-week screening period, a 6-week introduction period, a 24 week double-blind treatment period, a 24 week study extension period and a 4-week safety follow-up period.

Subjects who met the randomization criteria will be randomly assigned to the IBI362 4.0 mg group, the IBI362 6.0 mg group and the placebo group at 1:1:1. The randomization stratification factors were (V3) HbA1c<8.5% or HbA1c ≥ 8.5% before randomization.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: IBI362; Other: placebo

• Study Type: Interventional
• Enrollment (Actual): 319
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210008
      • Nanjing Drum Tower hospital
      • Contact: Dalong Zhu; Phone Number: +86-025-68182432; Email: zhudalong@nju.edc.cn
      • Contact: Jiajun Zhao; Phone Number: +86-15168889899; Email: jjzhao@sdu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. T2D was diagnosed according to WHO standards in 1999 for at least 2 months
2. Age ≥ 18 when signing the informed consent form
3. The blood glucose was not well controlled after simple diet and exercise within 2 months before screening, and the local laboratory tested 7.5% ≤ HbA1c ≤ 10.5% during screening
4. Maintain a stable diet and exercise lifestyle during the study
5. Subjects voluntarily signed the informed consent form and agreed to strictly follow the requirements of this protocol

Exclusion Criteria:

1. Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
2. Weight change>5% within 12 weeks before screening (chief complaint)
3. Used any oral hypoglycemic drugs within 2 months before screening; ≥ 3 oral hypoglycemic drugs have been used together more than 2 months before screening
4. Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes or gestational diabetes
5. There are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)
6. Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study
7. Pregnant or lactating women, or men or women who are fertile and unwilling to use contraception throughout the study period
8. The investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IBI362 4.0 mg; ①2mg, subcutaneously (SC), once a week* 4weeks; ②4mg, SC, once a week* 44weeks.	Drug: IBI362; IBI362 administered subcutaneously (SC) once a week.
Experimental: IBI362 6.0 mg; ①2mg, SC, once a week* 4weeks; ②4mg, SC, once a week* 4weeks； ③6mg, SC, once a week* 40weeks.	Drug: IBI362; IBI362 administered subcutaneously (SC) once a week.
Placebo Comparator: placebo; placebo, SC, once a week* 24weeks;2mg, SC, once a week* 4weeks;4mg, SC, once a week* 4weeks；6mg, SC, once a week* 16weeks.	Other: placebo; placebo administered subcutaneously (SC) once a week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
HbA1c change from baseline at week 24	Baseline, 24 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of subjects with HbA1c<7.0% at week 24	Baseline, 24 weeks
Safety, Incidence and severity of adverse events and correlation with study drug;	Baseline to 52 weeks
Time to peak plasma concentration (Tmax)	Baseline to 52 weeks
Time to peak plasma concentration (Cmax)	Baseline to 52 weeks
area under curve (AUC)	Baseline to 52 weeks
volume distribution (V)	Baseline to 52 weeks
half-life (half-life, T1/2)	Baseline to 52 weeks
clearance rate (clearance, CL)	Baseline to 52 weeks
To assess changes in PD parameters fasting insulin at different time points before and after administration.	Baseline to 52 weeks
To assess changes in PD parameters fasting C-peptide at different time points before and after administration.	Baseline to 52 weeks

Collaborators and Investigators

• Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2023
• Primary Completion (Actual): October 25, 2023
• Study Completion (Estimated): January 15, 2025

Study Registration Dates

• First Submitted: November 17, 2022
• First Submitted That Met QC Criteria: November 17, 2022
• First Posted (Actual): November 28, 2022

Study Record Updates

• Last Update Posted (Actual): November 21, 2023
• Last Update Submitted That Met QC Criteria: November 20, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: CIBI362A301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No